Bluejay Diagnostics shares are trading higher after the company announced SYMON-I study results showing that IL-6 levels within 24 hours of ICU admission predict 28-day mortality in sepsis and septic shock patients.
Portfolio Pulse from Benzinga Newsdesk
Bluejay Diagnostics shares are trading higher after the company announced positive SYMON-I study results. The study showed that IL-6 levels within 24 hours of ICU admission can predict 28-day mortality in sepsis and septic shock patients.
June 26, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bluejay Diagnostics shares are trading higher following the announcement of positive SYMON-I study results. The study demonstrated that IL-6 levels within 24 hours of ICU admission can predict 28-day mortality in sepsis and septic shock patients.
The positive results from the SYMON-I study are likely to boost investor confidence in Bluejay Diagnostics' capabilities and future prospects, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100